Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017

“Tumor Necrosis Factor Alpha (TNF-a) Inhibitors-Pipeline Insights 2017″, report provides comprehensive analysis of TNF-a drug candidates currently undergoing clinical trials. The report covers detailed drug profiles of potential TNF-a inhibitors across various clinical development phases including – discovery, pre-clinical, IND, Phase I, Phase II, Phase III and Pre-registration. Report also includes the pipeline products’ clinical trial data along with information on other development activities including technology, licensing, collaborations, acquisitions, funding, patent and USFDA & EMA designations. Report also assesses the pipeline TNF-a inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides detailed information on the discontinued and dormant drugs.

View report:https://www.arizton.com/reports/pharma-pipeline-analysis/tumor-necrosis-factor-alpha-tnf-a-inhibitors-pipeline-insights

Key players developing potential TNF-a drug candidates have been profiled in the report. Each of the company profile provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Advent Tumor Necrosis Factor Alpha (TNF-a) inhibitors represent one a major treatment paradigm for inflammatory diseases. Anti TNF-a drug class one of the most commercially successful drug classes in the pharmaceutical industry worldwide. Currently marketed anti-TNF-a drugs are among the top five global block buster drugs. Cumulative sales of top three TNF-a inhibitors (Remicade, Enbrel, Humira) surpassed $32 billion in 2016.

TNF-a inhibitors exhibit therapeutic efficacy blocking the activity of tumor necrosis factor (TNF), a cytokine that causes inflammation and leads to diverse immune-system diseases. Apparently, almost all the currently marketed TNF-a drugs are indicated for wide spectrum of immune-related disorders such as – Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and uveitis. Advances in biological research is uncovering further therapeutic benefits of this drug class for wider indications. Currently clinical research is focused on evaluating therapeutic efficacy and safety of TNF-a inhibitors on wide range of other inflammatory diseases, neurodegenerative diseases and multiple cancers.

Reasons to buy

To gain erudite insights on TNF-a inhibitor pipeline landscape
Ascertain unique product development dynamics and leverage it for novel target identification, drug repositioning and precision medicine.

For optimization of pipeline product portfolio in correspondence with ever dynamic pharmaceutical market

Identify competitors and design strategic initiatives for drug development activities

To understand the market and choose right partners for strategic collaborations

To obtain well-informed updates on drug termination/drug discontinuations

Related Reports

1) Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

https://www.arizton.com/reports/pharma-pipeline-analysis/histone-deacetylase-hdac-inhibitors-pipeline-insights

2) Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2017
https://www.arizton.com/reports/pharma-pipeline-analysis/chimeric-antigen-receptor-car-t-cell-immunotherapy-pipeline-insights-2017

About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.